Oddity Tech Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ODD research report →
Range $8 – $15
Price Chart
About the company
Operating globally, Oddity Tech Ltd. and its affiliated companies function as a consumer technology enterprise. It delivers beauty and wellness merchandise, leveraging its proprietary PowerMatch technology.
- CEO
- Oran Holtzman
- IPO
- 2023
- Employees
- 658
- HQ
- Jaffa, IL
Get TickerSpark's AI analysis on ODD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $709.04M
- P/E
- 13.82
- Fwd P/E
- 98.21
- PEG
- -0.27
- P/S
- 0.96
- P/B
- 2.34
- EV/EBITDA
- 12.60
- Div Yield
- 0.00%
- Gross Margin
- 71.09%
- Op Margin
- 6.84%
- Net Margin
- 6.97%
- ROE
- 14.45%
- ROIC
- 3.98%
Latest fiscal year · YoY change
- Revenue
- $809.84M+25.2%
- Gross Profit
- $588.71M+25.7%
- Op Income
- $118.77M
- Net Income
- $110.75M+9.1%
- EPS
- $1.95+9.6%
- OCF Growth
- -36.4%
- FCF Growth
- -35.5%
- 52W High
- $64.23
- 52W Low
- $9.25
- 50D MA
- $14.46
- 200D MA
- $23.23
- Beta
- 2.38
- RSI (14)
- 41
- Avg Volume
- 1.38M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ODDITY reported a steep Q1 revenue decline and negative EBITDA as a major ad-partner algorithm issue hurt customer acquisition, but management said May showed the first sequential CPA improvement and still expects full-year adjusted EBITDA to be positive.· June 2, 2026
- Q1 net revenue fell 26% year over year, slightly better than management’s prior expectation of about a 30% decline.
- Gross margin was 69.7%, down about 520 basis points year over year, and adjusted EBITDA was negative $7 million.
- Management said IL MAKIAGE CPA improved an estimated 28% from April to May, the first sequential recovery since Q4 ’25.
- The company said it shifted 40% of acquisition revenue out of Try Before You Buy into standard Buy by the end of Q1, with no impact on unit economics.
- Full-year adjusted EBITDA is still expected to be positive, while Q2 revenue is expected to decline 25% to 30% year over year.
Q1 net revenue declined 26% year over year, with first orders down around 50% and repeat orders down around 15%. Gross margin was 69.7%, compressing approximately 520 basis points year over year. Adjusted EBITDA was negative $7 million, adjusted diluted EPS was negative $0.17, and free cash flow was negative $21 million. The company ended Q1 with $667 million of cash, cash equivalents and investments, and $350 million of amended credit facilities remained undrawn. For Q2, management expects net revenue to decline 25% to 30% year over year and adjusted EBITDA to be between $8 million and $10 million. Full-year adjusted EBITDA is expected to be positive.
Oran Holtzman framed the quarter as a technical and algorithmic disruption at the company’s largest advertising partner, not a brand-health problem. He said the team is working closely with the partner and has seen a meaningful improvement in May, while continuing to spend enough to test fixes and recalibrate the system. His tone was defensive but optimistic, repeatedly saying the company believes the issue is solvable and that it wants to return to growth and profitability once CPA normalizes.
Lindsay Mann said the revenue decline was driven mainly by first orders, which fell about 50% because acquisition efficiency deteriorated, while repeat orders fell about 15%. She noted gross margin of 69.7%, adjusted EBITDA of negative $7 million, adjusted diluted EPS of negative $0.17, and free cash flow of negative $21 million. On liquidity and capital allocation, she said the company finished with $667 million of cash, cash equivalents and investments, $350 million of undrawn credit facilities, and about $167 million remaining under the new $200 million buyback authorization after repurchasing approximately 6 million shares for about $82 million.
Analysts focused on the path back to profitability, the cadence of EBITDA through the year, and whether May’s CPA improvement was enough to change the revenue outlook. Management said it did not provide quarterly back-half EBITDA guidance because visibility remains limited, but it still expects full-year adjusted EBITDA to be positive and said CPA is the key leading indicator. They also said lower acquisition spend is deliberate, meant to keep testing and support recovery, and that the Q2 guide assumes CPA remains difficult rather than fully normalizing.
The bullish read is that May was the first sequential CPA improvement in months, with IL MAKIAGE CPA down an estimated 28% from April, and management believes the partner can recover 40% to 60% of CPA from system fixes alone. Repeat behavior among existing customers remained strong, and the company still expects full-year adjusted EBITDA to be positive despite the disruption. Management also highlighted METHODIQ momentum and said the brand is on track for $25 million in revenue this year.
The bear case is that the company is still dealing with an unresolved acquisition problem at its most important ad partner, and management said this will have a meaningful negative impact on 2026 results, especially in H1. First orders were down about 50%, revenue fell 26%, and management said the overhang from lost first orders will continue to weigh on repeat sales for the rest of the year. They also said visibility into the back half is limited and that they cannot yet say when growth will resume, with 2027 also potentially affected by the loss of new users in 2026.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.3%
- Shares Outstanding
- 57.00M
- Float Shares
- 34.92M
of shares held by institutions
201 13F filers
Buy/sell ratio 1.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 2.09M | ▼ 337.00K |
| Ashford Capital Management Inc | 654.56K | ▼ 31.41K |
| Two Sigma Advisers, LP | 108.30K | ▼ 192.79K |
| Rip Road Capital Partners LP | 99.89K | ▲ 14.30K |
| California State Teachers Retirement System | 43.38K | ▼ 151 |
| Vanguard Group Inc | 35.34K | ▲ 853 |
| Nebula Research & Development LLC | 30.24K | ▲ 10.10K |
| Wolverine Trading, LLC | 5.54K | ▲ 5.54K |
| Atria Wealth Solutions, Inc. | 3.90K | ▲ 3.90K |
| Cwm, LLC | 100 | ▼ 75 |
| First Horizon Advisors, Inc. | 9 | ▲ 9 |
Held by 101 ETFs
Biggest fund positions in ODD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 5, 26 | Drucker Mann Lindsay | sell | 11,473 |
| Jul 31, 26 | Drucker Mann Lindsay | other | 23,929 |
| Jul 31, 26 | Drucker Mann Lindsay | other | 23,929 |
| Jul 29, 26 | Nir Yehoshua | other | 10,889 |
| Jul 28, 26 | Nir Yehoshua | other | 4,596 |
| Jul 28, 26 | Nir Yehoshua | other | 4,596 |
| Jul 28, 26 | Cheresniya Ohad | other | 4,596 |
| Jul 29, 26 | Cheresniya Ohad | other | 10,889 |
| Jul 28, 26 | Cheresniya Ohad | other | 4,596 |
| Jul 28, 26 | Payorski Lilach | other | 4,596 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ODD coverage
Recent articles, reports, and earnings notes.
No research on ODD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ODD report →Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
gurufocus.com · Aug 19
ODDITY Tech Ltd (ODD) Shares Surge 3.4% -- What GF Score of 77 Tells Investors
gurufocus.com · Aug 12
Empowered Funds LLC Takes Position in ODDITY Tech Ltd. $ODD
defenseworld.net · Aug 9
Amundi Grows Position in ODDITY Tech Ltd. $ODD
defenseworld.net · Aug 6
Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
gurufocus.com · Aug 6
U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
gurufocus.com · Aug 3
ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026
globenewswire.com · Jul 22
Fosun International Garners Five Awards from Corporate Governance Asia
gurufocus.com · Jul 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.